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Background: The recent Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) 
study found that statin therapy prevented vascular events in adults with elevated high-sensitivity C-reactive protein (hs-CRP) but low low-density 
lipoprotein (LDL) cholesterol. It is estimated that an additional 6 to 8 million adults in the United States would have a statin indication based 
on JUPITER inclusion criteria. Previous analysis found that the incremental cost-effectiveness for coronary heart disease (CHD) prevention in this 
population was $53,980/quality-adjusted life year (QALY). This study estimates the cost-effectiveness of statin therapy in this population for CHD 
and stroke prevention.
Methods: A Markov decision-analytic model was used to simulate the average adult population in the US with elevated hs-CRP (≥2 mg/L) and low 
LDL cholesterol (<130 mg/dL). Data from JUPITER were used to estimate rates of myocardial infarction, angina and stroke in this population, with 
and without statin therapy. Costs for statin therapy, vascular events, and adverse events were calculated from the societal perspective. Statin costs 
were based on 80mg generic Simvastatin, equipotent to the dose used in JUPITER. QALYs were calculated using nationally representative preference-
based utility weights. One-way sensitivity analyses were performed to determine factors influencing costs and effects. Probabilistic sensitivity analysis 
was used to determine the probability of cost-effectiveness when all event rates, costs and utilities were drawn randomly from distributions reflecting 
uncertainty.
Results: Statin therapy cost $40,457/QALY for CHD and stroke prevention in this population. This estimate was highly sensitive to statin cost. 
Based on 10,000 simulations, statin therapy was cost-effective 92% of the time, using a willingness-to-pay threshold of $50,000/QALY, and 100% of 
the time using a threshold of $100,000/QALY.
Conclusion: For adults with low LDL cholesterol but elevated hs-CRP, statin therapy for stroke and CHD prevention is cost-effective at a lower 
willingness-to-pay than for CHD prevention alone.
